## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($91.80)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Incyte Corp. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20251215T163000 | Bullish | Relevance: 100%
- Incyte Corp. (INCY) shares rose 3.39% to $98.64 on a challenging trading day, outperforming the S&P 500 and Dow Jones Industrial Average which experienced slight declines. Despite the gain, Incyte Corp. closed 9.73% below its 52-week high of $109.28 reached on November 12th. The article highlights Incyte's strong performance relative to the broader market.

**2. Incyteâ€™s latest study completion: A step forward in drug interaction insights**
- Source: MSN | 20251216T010832 | Bullish | Relevance: 100%
- The article reports that Incyte has completed its latest study. This completion marks a step forward in gaining drug interaction insights, though no specific drug or study details are provided in this brief update.

**3. Incyte Lures New Top Lawyer With Hefty Equity Package Tied to Performance**
- Source: MyChesCo | 20251213T170806 | Somewhat-Bullish | Relevance: 100%
- Incyte Corporation (INCY) has appointed Richard Hoffman as its new Executive Vice President and General Counsel, attracting him with a substantial equity-based compensation package. This package includes stock options, restricted stock units, and performance-based shares, designed to align Hoffman's long-term interests with the company's performance. The move highlights Incyte's strategy to secure top talent in a competitive market while emphasizing shareholder alignment.

**4. Bellevue Group AG Has $106.94 Million Holdings in Incyte Corporation $INCY**
- Source: MarketBeat | 20251213T110827 | Neutral | Relevance: 100%
- Bellevue Group AG recently reduced its stake in Incyte Corporation by 24.9% in the 2nd quarter, now holding 1,570,333 shares valued at approximately $106.94 million, representing 0.80% of Incyte's stock. Several other institutional investors have also adjusted their positions in Incyte, and company insiders have sold shares totaling over $2.7 million in the last quarter. Incyte's stock opened at $95.41 with a market cap of $18.73 billion, and analysts project $4.86 EPS for the current fiscal year, with an average "Hold" rating and a consensus target price of $99.07.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Morgan Stanley | $92 | $86 | +7% |
| 2025-12-08 | Wells Fargo | $116 | $97 | +20% |
| 2025-12-08 | Mizuho | $121 | $90 | +34% |
| 2025-11-24 | Barclays | $115 | $101 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Wells Fargo | main | Overweight |
| 2025-12-08 | Mizuho | up | Outperform |
| 2025-11-24 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($0.15M) |
| Sells | 15 ($23.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Heavy insider selling: $23M sold (15 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +19%) could attract flows.
- Momentum building: MRS_10 improving +9.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.12 indicates undervaluation relative to growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (4 raises, avg +19%). Insider selling cluster ($23.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.4B |
| Beta | 0.81 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 6.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.12 |
| Forward P/E | 12.8 |
| Current P/E | 14.4 |
| YoY Growth | 12.7% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -7.0% to 2.1% (+9.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.9pp (needs >3.0% for momentum thesis). MRS_5 at 4.2% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.28x) but short-term weakness (below SMA20). MACD histogram bearish (-1.09), momentum weakening. RSI neutral at 48. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.07% (CS: 49) | Neutral |
| RSI_14 | 48.5 | Neutral |
| MACD Histogram | -1.09 | Bearish |
| vs SMA20 | 0.977x | Below |
| vs SMA50 | 1.019x | Above |
| vs SMA200 | 1.277x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $98.64
- **Stop Loss:** $91.80 (6.9% risk)
- **Target:** $105.48 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 175
- **Position Value:** $17,262.00
- **Portfolio %:** 17.26%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-09 (Est: $1.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*